Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis

Breast Cancer Research and Treatment

Volumn 152, Issue 2, 2015, Pages 407-416

  Fouad, Tamer M ^a,b   Kogawa, Takahiro ^a   Liu, Diane D ^a   Shen, Yu ^a   Masuda, Hiroko ^a   El Zein, Randa ^a   Woodward, Wendy A ^a   Chavez MacGregor, Mariana ^a   Alvarez, Ricardo H ^a   Arun, Banu ^a   Lucci, Anthony ^a   Krishnamurthy, Savitri ^a   Babiera, Gildy ^a   Buchholz, Thomas A ^a   Valero, Vicente ^a   Ueno, Naoto T ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b CAIRO UNIVERSITY   (Egypt)

Author keywords

Breast cancer; IBC; Inflammatory breast cancer; Metastasis; Prognosis; Stage IV

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TUMOR MARKER;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BLACK PERSON; BREAST CANCER; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER STAGING; CAUCASIAN; DISTANT METASTASIS; FEMALE; FOLLOW UP; HUMAN; INFLAMMATORY BREAST CANCER; MAJOR CLINICAL STUDY; NONINFLAMMATORY BREAST CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SURVIVAL RATE; SURVIVAL TIME; VERY ELDERLY; VISCERAL METASTASIS; BREAST NEOPLASMS; INFLAMMATORY BREAST NEOPLASMS; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; BREAST NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFLAMMATORY BREAST NEOPLASMS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; YOUNG ADULT;

EID: 84946489232     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-015-3436-x     Document Type: Article

References (36)

1. Edge S, Byrd D, Compton C (2010) American Joint Committee on Cancer (AJCC) staging handbook. Springer, New York
2. Dawood S, Merajver SD, Viens P et al (2011) International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Ann Oncol 22:515–523
3. Anderson WF, Schairer C, Chen BE et al (2005) Epidemiology of inflammatory breast cancer (IBC). Breast Dis 22:9–23
4. Hance KW, Anderson WF, Devesa SS et al (2005) Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute. J Natl Cancer Inst 97:966–975
5. Jaiyesimi IA, Buzdar AU, Hortobagyi G (1992) Inflammatory breast cancer: a review. J Clin Oncol 10:1014–1024
6. Wingo PA, Jamison PM, Young JL, Gargiullo P (2004) Population-based statistics for women diagnosed with inflammatory breast cancer (United States). Cancer Causes Control 15:321–328
7. Elias EG, Vachon DA, Didolkar MS, Aisner J (1991) Long-term results of a combined modality approach in treating inflammatory carcinoma of the breast. Am J Surg 162:231–235
8. Curcio LD, Rupp E, Williams WL et al (1999) Beyond palliative mastectomy in inflammatory breast cancer—a reassessment of margin status. Ann Surg Oncol 6:249–254
9. Miller KD, Sledge GW Jr (1999) The role of chemotherapy for metastatic breast cancer. Hematol Oncol Clin N Am 13:415–434
10. O’Shaughnessy J (2005) Extending survival with chemotherapy in metastatic breast cancer. Oncologist 10(Suppl 3):20–29
11. Lu J, Steeg PS, Price JE et al (2009) Breast cancer metastasis: challenges and opportunities. Cancer Res 69:4951–4953
12. Cristofanilli M, Valero V, Buzdar AU et al (2007) Inflammatory breast cancer (IBC) and patterns of recurrence: understanding the biology of a unique disease. Cancer 110:1436–1444
13. Dawood S, Ueno NT, Valero V et al (2011) Differences in survival among women with stage III inflammatory and noninflammatory locally advanced breast cancer appear early: a large population-based study. Cancer 117:1819–1826
14. Low JA, Berman AW, Steinberg SM et al (2004) Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapy. J Clin Oncol 22:4067–4074
15. National Comprehensive Cancer Network (2014) NCCN guidelines, version 3.2014, invasive breast cancer. BINV-17
16. Hammond ME, Hayes DF, Dowsett M et al (2010) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28:2784–2795
17. Wolff AC, Hammond ME, Hicks DG et al (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 31:3997–4013
18. Schemper M, Smith TL (1996) A note on quantifying follow-up in studies of failure time. Control Clin Trials 17:343–346
19. Robins JM, Rotnitzky A (2001) Comment on the Bickel and Kwon Article, “Inference for semiparametric models: some questions and an answer”. Stat Sin 11:920–936
20. Austin PC (2008) The performance of different propensity-score methods for estimating relative risks. J Clin Epidemiol 61:537–545
21. Andre F, Slimane K, Bachelot T et al (2004) Breast cancer with synchronous metastases: trends in survival during a 14-year period. J Clin Oncol 22:3302–3308
22. Campone M, Bachelot T, Gnant M et al (2013) Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: subgroup analysis from the BOLERO-2 study. Eur J Cancer 49:2621–2632
23. Dawood S, Ueno NT, Valero V et al (2012) Identifying factors that impact survival among women with inflammatory breast cancer. Ann Oncol 23:870–875
24. Sutherland S, Ashley S, Walsh G et al (2010) Inflammatory breast cancer—the Royal Marsden Hospital experience: a review of 155 patients treated from 1990 to 2007. Cancer 116:2815–2820
25. Panades M, Olivotto IA, Speers CH et al (2005) Evolving treatment strategies for inflammatory breast cancer: a population-based survival analysis. J Clin Oncol 23:1941–1950
26. Masuda H, Baggerly KA, Wang Y et al (2013) Comparison of molecular subtype distribution in triple-negative inflammatory and non-inflammatory breast cancers. Breast Cancer Res 15:R112
27. Slamon DJ, Clark GM, Wong SG et al (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177–182
28. Seshadri R, Firgaira FA, Horsfall DJ et al (1993) Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group. J Clin Oncol 11:1936–1942
29. Dawood S, Broglio K, Buzdar AU et al (2010) Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol 28:92–98
30. Iwamoto T, Bianchini G, Qi Y et al (2011) Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancer. Breast Cancer Res Treat 125:785–795
31. Iwamoto T, Bianchini G, Booser D et al (2011) Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer. J Natl Cancer Inst 103:264–272
32. Beslija S, Bonneterre J, Burstein HJ et al (2009) Third consensus on medical treatment of metastatic breast cancer. Ann Oncol 20:1771–1785
33. Khan SA (2007) Does resection of an intact breast primary improve survival in metastatic breast cancer? Oncology (Williston Park) 21:924–931; discussion 931–922, 934, 942, passim
34. Morrow M, Goldstein L (2006) Surgery of the primary tumor in metastatic breast cancer: closing the barn door after the horse has bolted? J Clin Oncol 24:2694–2696
35. Gonzalez-Angulo AM, Hennessy BT, Broglio K et al (2007) Trends for inflammatory breast cancer: is survival improving? Oncologist 12:904–912
36. Tsai CJ, Li J, Gonzalez-Angulo AM et al (2013) Outcomes after multidisciplinary treatment of inflammatory breast cancer in the era of neoadjuvant HER2-directed therapy. Am J Clin Oncol 38:242–247